Project Grant R01DE033396

Award Date 8/9/24
Completion Date 5/31/29
Dollars Obligated $1.4M
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop microphysiological systems (MPSs) that can recapitulate the complex pathogenesis of Sjogren's disease (SjD), a systemic autoimmune condition affecting the salivary glands. The $196,459 award, effective from August 1, 2025 to July 31, 2027, will support research to investigate how collagen density and the presence...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), provides $248,750.00 to the ADA Forsyth Institute, Inc. (The Forsyth Institute) to investigate the role of cellular senescence in salivary gland dysfunction associated with Sjögren's syndrome. The research aims to determine the impact of cellular senescence on Sjögren's syndrome-related xerostomia (dry mouth) and...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $231,492 to develop an in vitro salivary gland Sjogren's syndrome (SS) tissue chip (SSTC) platform. The goal is to use this SSTC platform to investigate the effects of endocrine-disrupting chemicals on the growth and function of salivary gland tissue mimetics. The project will also perform RNA sequencing studies...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $714,711 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, which commenced on July 1, 2025, aims to investigate mechanisms that can specifically protect or regenerate salivary glands without benefiting cancer growth following radiation therapy. The research team developed a scalable gene targeting system to screen over...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, is providing $429,000 to the University of South Alabama to conduct research on targeting phosphodiesterase 4 (PDE4) enzymes as a potential therapeutic approach for alleviating xerostomia (dry mouth) in Sjögren's syndrome. The research aims to evaluate the therapeutic benefits of selectively inhibiting specific PDE4 subtypes,...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), part of the Oral Diseases and Disorders Research program (CFDA 93.121), provides $628,965.00 to the Icahn School of Medicine at Mount Sinai over a 5-year period from May 1, 2025 to April 30, 2030. The funding supports research to elucidate how immune cells, specifically tissue-resident macrophages, regulate the coordinated processes of salivary gland development and differentiation. The...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), is providing $100,676 to the Icahn School of Medicine at Mount Sinai to conduct research on defining the role of tissue-resident macrophages during salivary gland morphogenesis. The research aims to determine the functional contribution of these macrophages to salivary gland development and characterize their role in...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $115,992 to The Research Foundation For The State University Of New York (RF SUNY) to develop human induced pluripotent stem cell (iPSC)-derived salivary gland organoids (SGOs) with secretory function and well-defined architecture. The project aims to utilize engineered viscoelastic hydrogels to optimize the...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), provides $465,376 to the University of California, Los Angeles (UCLA) to develop a saliva-based electrochemical assay for the early detection of Sjögren's disease (SJD) and its precursor autoimmune-sicca syndrome (AI-sicca). The key objectives are to: 1) detect anti-SSA/Ro52 and anti-SSB/La autoantibodies in the...
The Research Foundation for the State University of New York (RF-SUNY) has been awarded a $300,000 "Trans-NIH Research Support" Project Grant (CFDA 93.310) from the National Institutes of Health (NIH) Office of the Director. The purpose of this 1-year award, effective September 1, 2023, is to investigate the role of cellular senescence and associated inflammatory signaling (the senescence-associated secretory phenotype or SASP) in promoting salivary gland dysfunction in Sjogren's...

This federal Project Grant award of $1,386,899.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program. The grant aims to define how Sjögren's disease endotypes modify the immunobiology of salivary gland mesenchymal stromal cells, comparing mouse and human models. The research will use JAK inhibitors as immunopharmacological probes to determine the signaling pathways driving maladaptive mouse mesenchymal stromal cells and investigate the pathologic responses and heterogeneity of human mesenchymal stromal cells across Sjögren's disease endotypes. The grant involves a sub-award to the Georgia Tech Research Corporation to support single-cell and spatial profiling of murine and human mesenchymal stromal cells in the biopsy-positive Sjögren's disease endotype. The overall goal is to clarify the pathobiology of salivary gland mesenchymal stromal cells by endotype, which could enable new targeted therapies for Sjögren's disease.

Generated 8/5/25, 6:24 AM